1
2
3
4
5
Cherney, David Z I, Dekkers, Claire C J, Barbour, Sean J, Cattran, Daniel, Abdul Gafor, Abdul Halim, Greasley, Peter J, Laverman, Gozewijn D, Lim, Soo Kun, Di Tanna, Gian Luca, Reich, Heather N, Vervloet, Marc G, Wong, Muh Geot, Gansevoort, Ron T, Heerspink, Hiddo J L
Veröffentlicht in: DIAMOND investigators , Cherney , D Z I , Dekkers , C C J , Barbour , S J , Cattran , D , Abdul Gafor , A H , Greasley , P J , Laverman , G D , Lim , S K , Di Tanna , G L , Reich , H N , Vervloet , M G , Wong , M G , Gansevoort , R T & Heerspink , H J L 2020 , ' Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND) : a randomised, double-blind, crossover trial ' , Lancet Diabetes & Endocrinology , vol. 8 , no. 7 , pp. 582-593 . https://doi.org/10.1016/S2213-8587(20)30162-5;
2020
Veröffentlicht in: DIAMOND investigators , Cherney , D Z I , Dekkers , C C J , Barbour , S J , Cattran , D , Abdul Gafor , A H , Greasley , P J , Laverman , G D , Lim , S K , Di Tanna , G L , Reich , H N , Vervloet , M G , Wong , M G , Gansevoort , R T & Heerspink , H J L 2020 , ' Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND) : a randomised, double-blind, crossover trial ' , Lancet Diabetes & Endocrinology , vol. 8 , no. 7 , pp. 582-593 . https://doi.org/10.1016/S2213-8587(20)30162-5;
2020